Banked Bone Marrow Could Rebuild Aging Immune Systems at Scale
Ossium Health is banking donor bone marrow for on-demand transplant, targeting immune aging as a future healthspan intervention.
20 articles
Ossium Health is banking donor bone marrow for on-demand transplant, targeting immune aging as a future healthspan intervention.
Beijing's 301 Hospital begins recruiting adults 50+ for the world's largest stem cell antiaging clinical trial using an already-approved therapy.
A new perspective outlines how stem cells, bioprinted organs, and cross-species genes could replace โ not just repair โ aging biology.
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
Heartseed's iPSC-derived heart cell therapy enters Phase I/II trial for dilated cardiomyopathy, with first patient data cleared by safety board.
Scarlet Therapeutics grows universal red blood cells that survive as long as donated ones, opening a path to engineered therapeutic blood.
RBI's Wnt-activated stem cells injected directly into the brain show early promise reducing tau and amyloid markers in Phase 1.
A rare stress-enduring stem cell subpopulation called Muse cells could solve regenerative medicine's biggest failures and slow tissue aging.
A new wave of biotechs is targeting aging as a root cause, using encapsulated cells and gene therapy to restore lost proteins and reverse decline.
Aspen Neuroscience's stem cell therapy restored dopamine neurons in Parkinson's patients, adding ~2 hours of controlled movement daily.
Rockefeller scientists reprogrammed blood stem cells to produce rare broadly neutralizing antibodies, offering a potential one-time immunity platform.
Xenotransplantation, 3D bioprinting, and stem cell therapies are converging to solve the global organ shortage crisis.
Biotech company secures funding to move lab-grown human tissue implants toward clinical trials, starting with adipose tissue.
A rare stress-resilient cell type may solve the biggest failure in stem cell therapy: most injected cells never reach damaged tissue.
A dual therapy clearing senescent cells and restoring stem cell function dramatically extended mouse lifespan in a new preclinical study.
Astellas reports encouraging early-stage results for a stem cell-derived treatment targeting age-related eye disease, though data remains limited.
Cellares raises $277M to scale robotic CAR T manufacturing after delivering first GMP-grade doses to patients, signaling a shift from science to supply.
CellProthera's ProtheraCytes targets heart repair post-myocardial infarction, aiming to prevent heart failure before damage becomes irreversible.
Sana Biotechnology and Mayo Clinic are advancing SC451, a cell therapy that may restore natural insulin production without immunosuppression.
Chinese biotech begins multicenter trial of stem cell therapy showing promising early results for Parkinson's motor symptoms and quality of life.